BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 38658967)

  • 1. LRG1 Contributes to the Pathogenesis of Multiple Kidney Diseases: A Comprehensive Review.
    Chen C; Zhang J; Yu T; Feng H; Liao J; Jia Y
    Kidney Dis (Basel); 2024 Jun; 10(3):237-248. PubMed ID: 38799248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
    Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
    BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRG1 May Accelerate the Progression of ccRCC via the TGF-
    Hong Q; Wang S; Liu S; Chen X; Cai G
    Biomed Res Int; 2020; 2020():1285068. PubMed ID: 32337221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Utility of Serum Leucine-Rich α-2-Glycoprotein 1 for Acute Appendicitis in Children.
    Tintor G; Jukić M; Šupe-Domić D; Jerončić A; Pogorelić Z
    J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer.
    Yamamoto M; Takahashi T; Serada S; Sugase T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Naka T; Mori M; Doki Y
    Cancer Sci; 2017 Oct; 108(10):2052-2060. PubMed ID: 28746773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
    Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
    Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma.
    Wang Y; Xing Q; Chen X; Wang J; Guan S; Chen X; Sun P; Wang M; Cheng Y
    Curr Cancer Drug Targets; 2019; 19(9):756-763. PubMed ID: 30714525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure.
    Song W; Wang X
    Biophys Rev; 2015 Mar; 7(1):91-104. PubMed ID: 28509980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of Diagnostic Accuracy: Basic Definitions.
    Šimundić AM
    EJIFCC; 2009 Jan; 19(4):203-11. PubMed ID: 27683318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Escudier B; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Choueiri TK; Gurney H; Donskov F; Bono P; Wagstaff J; Gauler TC; Ueda T; Tomita Y; Schutz FA; Kollmannsberger C; Larkin J; Ravaud A; Simon JS; Xu LA; Waxman IM; Sharma P;
    N Engl J Med; 2015 Nov; 373(19):1803-13. PubMed ID: 26406148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.
    Hsiao W; Herrel LA; Yu C; Kattan MW; Canter DJ; Carthon BC; Ogan K; Master VA
    Int J Urol; 2015 Mar; 22(3):264-70. PubMed ID: 25428139
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.